Topic: triple-negative breast cancer
A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.
Immunomedics has had a long and troubled road in the past few years that has included losing much of its C-suite after an FDA rejection.
Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.
Insilico Medicine has signed a dual-program discovery collaboration with Jiangsu Chia Tai Fenghai Pharmaceutical worth up to $200 million.
A drug that causes cancer cells to divide too rapidly and die was effective when combined with chemo in mouse models of triple-negative breast cancer.
People who received the CDK4/6 inhibitor lived 20.1 months, on average, as compared to 12.6 months for their peers in the chemotherapy cohort.
Moncef Slaoui and his colleagues at Medicxi have taken the wraps off a new oncology startupt hat wants to interrupt cancer cell-to-cell communication.
Atomwise launched two joint ventures—one testing drugs in tumor organoids, and one to develop epigenetic drugs for triple-negative breast cancer.
A Boston Children's team has developed a method for knocking out the oncogene Lipocalin 2 using CRISPR carried by soft nanoparticles.
Ayala's pan-Notch, gamma secretase inhibitor AL101 showed positive response in triple-negative breast cancer patient-derived xenograft models.